Immuno-oncology is moving beyond first-generation checkpoint inhibitors, with new approaches such as bispecific antibodies, T-cell engagers, and biomarker-led strategies shaping how trials are designed.
As these therapies advance, sponsors face growing challenges around patient selection, trial design, and meeting regulatory requirements.
In this roundtable summary, Novotech and industry experts share perspectives on how to approach immuno-oncology clinical trials and compete in an increasingly crowded field.
Download the summary to learn:
- How biomarker-led approaches are influencing treatment development
- Why adaptive trial design is important in early-phase studies
- Key challenges in patient recruitment and site engagement
- How regulatory expectations are changing
Listen to the related podcast here: https://novotech-cro.com/podcasts/beyond-checkpoint-next-gen-strategies-immuno-oncology